Cases & Deals

  • Home
  • Practices
  • MGI US and Complete Genomics grant license to Swiss Rockets to develop, manufacture, and commercialize CoolMPS™ sequencing technology

Share

MGI US and Complete Genomics grant license to Swiss Rockets to develop, manufacture, and commercialize CoolMPS™ sequencing technology

October 2025

Client(s) MGI US LLC and Complete Genomics Inc.

Jones Day represented MGI US LLC ("MGI") and Complete Genomics Inc. ("CGI"), U.S. subsidiaries of China-based MGI Tech Co., Ltd., in connection with a license agreement with Swiss Rockets AG ("Swiss Rockets"), a Switzerland-based biotech firm. Under the license agreement, MGI and CGI grant Swiss Rockets a license to research, develop, manufacture, and commercialize sequencing products based on MGI's and CGI's CoolMPS™ technology, outside the Asia-Pacific and Greater China regions (i.e., Chinese Mainland, Hong Kong, Macau, and Taiwan). The agreement includes payments linked to technology transfer and revenue-based royalties. CoolMPS™ technology, distinguished by its innovative antibody or binding molecule-based recognition chemistry, represents a breakthrough in sequencing. Swiss Rockets will leverage the license to further expand CoolMPS™'s global reach and applications by manufacturing CoolMPS™ sequencers and consumables for markets including U.S. and Europe. The technology and its products will also be used to augment the company's personalized disease and aging prevention and optimal disease treatments aimed at precision longevity and medicine.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.